A method for the treatment of deep venous thrombosis of the lower extremities
The invention relates to medicine, to methods afferent therapy and can be used for the treatment of deep venous thrombosis of the lower extremities. Before the blood sampling of the patient's veins are 50-70 U/kg of heparin, produce blood from the patient's vein 2-4 ml per kg of body weight of the patient, carry out ultraviolet irradiation collected blood at an average dose of 1 j/cm2the area of the irradiated surface of the cell is equal to 30 cm2, further is carried out 2 times a week discrete plasmapheresis blood, the velocity of blood is 25-40 ml/min and the extraction of plasma per procedure is 8-10 ml/kg, simultaneously administered to the patient angioprotectors. This invention improves the effectiveness of treatment of deep venous thrombosis of the lower extremities, speeding the process of recanalization and prevent the development of trophic disorders prior recanalization. 4 Il.The invention relates to medicine, in particular to methods and means of treatment of deep venous thrombosis of the lower extremities.The closest in technical essence and the achieved effect is the method of treatment is the ATA. Such as direct anticoagulants, such as heparin for 5 days followed by transfer to indirect anticoagulants, such as warfarin for 3 months (O. K. Laurence, Clinical Pharmacology, 1987). Fibrinolytic drugs in the proximal thrombosis are of limited use in connection with late (>7 days) treatment of patients.The disadvantage of this method of treatment is the fact that the use of anticoagulants causes a number of side effects: the use of direct anticoagulants may include bleeding, thrombocytopenia, “rebound” effect when you cancel heparin; with long-term administration of the drug may cause osteoporosis, the transient alopecia.The effect of indirect anticoagulants can cause bleeding, especially in patients with ischemic cerebrovascular disease, venous thromboembolism and ischemic heart disease. Contraindications to the use of indirect anticoagulants during pregnancy due to penetration through the placental barrier. Despite treatment, the process of organizing thrombus with recanalization of the venous bed is quite slow.The average stage mechanisatie is accompanied by the appearance by this time, trophic disorders. The technical result, which directed the establishment of this invention is to increase efficiency of treatment of deep-vein thrombosis of the lower extremities, by speeding up the process of recanalization with an average of 4 years to 1.5 years and prevent the development of trophic disorders prior recanalization.Theoretical background of the proposed method of treatment are the data reported in A. Vogt, Shimisi P. // Kidney Int. - 1982. - Vl.22. - R. 27-35; Konstantinova, I. A. Evaluation of pathogenic and non-pathogenic immune complexes. - M.: Method. Recommendations the Ministry of health, USSR, 1986, Konstantinova N. A., Lavrentiev centuries, Kovalchuk L. C., Petrov R. C. Determination of circulating immune complexes in humans // Laboratory work. - 1982. No. 11. -S. 673-676.They define the correlation relationship between the excess of circulating immune complexes (CIC), activation of the hemostatic system and inhibition of the complement system. Emphasizing the important role of the reticuloendothelial system (RES) in the natural process of fibrinolysis, the authors point to the presence of functional block RES amid excess of circulating immune complexes (CIC). This leads to slow and perversion (thrombus) lysis of the thrombus. Our research shows criminalities activity the increase of acute phase proteins (seromucoid), immunoglobulins and CEC. And, significantly reduced the level of cell-mediated immunity (CD) is not restored to the stage of complete recanalization of the thrombus. In Fig.1 shows the dynamics of changes in cellular immunity (CD) and complement activity (KA) in patients with postthrombotic disease in the stage of occlusion. These changes are characteristic of the immune process.In the proposed method of treatment, the effects of exercise on the system reticuloendothelial system (RES). The activation functions of the macrophage system, "unlocking receptors RES" (Lookwood C. M., Peters D. K. Ann Rev. Med., 1980, v.31, R. 167-169; Cjrdonnier D., Vialtel P., Chenais F. et al. - In: Plasma Exchange. Stuttgart, 1980, p.213-219; Gibert E. B., Silver N. B. and other Endogenous photomodification functional state of cells // Efferent therapy, 1995, T. 1, No. 3. - S. 56-58).Normalization of hemostasis occurs secondarily and indirectly, through normalization of the level of circulating immune complexes (CIC).The technical result - increase of efficiency of treatment of deep venous thrombosis of the lower extremities, speeding up the process of recanalization and the prevention of the development of trophic disorders before the period of racanelli macrophage system and “unlocking” of the receptors of the reticuloendothelial system.The technical result is achieved in that in the method of treatment of deep venous thrombosis of the lower extremities based on the use of drugs injected into a vein of the patient 50-70 U/kg of heparin, produce blood from the patient's vein 2-4 ml per kg of body weight, carry out ultraviolet irradiation collected blood at an average dose of 1 j/cm2, then hold 2 times a week discrete plasmapheresis blood, simultaneously administered to the patient angioprotectors.A method for the treatment of deep venous thrombosis of the lower extremities is as follows: before the blood sampling of the patient's veins are 50-70 U/kg of heparin. Produce drawing blood from a vein of the patient in 2-4 ml per kg of body weight of the patient, carry out ultraviolet irradiation collected blood at an average dose of 1 j/cm2the area of the irradiated surface of the cell is equal to 30 cm2.Then hold 2 times a week discrete plasmapheresis blood, the velocity of blood is 25-40 ml/min and the extraction of plasma per procedure is 8-10 ml/kgThe number of treatments plasmapheresis calculated with respect to exchange of plasticstoday 75-the Oia donor preparations by a combination of hemocorrection (poliglyukin, reopoliglyukin, gemodez) and crystalloid solutions (1:3). At the same time the patient is given angioprotectors.Ultraviolet blood irradiation produced by the apparatus of the MD-73M “Isolde” with mercury germicidal lamp [DRB] 8-1 to 8 watts, reversible motor RD-09.Plasmapheresis is produced using a refrigerated centrifuge RS-6 in g mode=1800, T=20-25








Claims
A method for the treatment of deep venous thrombosis of the lower extremities based on the use of drugs, characterized in that before the blood sampling of the patient's veins are 50-70 U/kg of heparin, produce blood from the patient's vein 2-4 ml per kg of body weight of the patient, carry out ultraviolet irradiation collected blood at an average dose of 1 j/cm2the area of the irradiated surface of the cell is equal to 30 cm2, further is carried out 2 times a week discrete plasmapheresis blood, the velocity of blood is 25-40 ml/min and the extraction of plasma per procedure is 8-10 ml/kg, simultaneously administered to the patient angioprotectors.
FIELD: medicine, oncology.
SUBSTANCE: the present innovation deals with treating patients with uterine cervix cancer with relapses in parametral fiber and in case of no possibility for radical operative interference and effect of previous radiation therapy. During the 1st d of therapy one should intravenously inject 30 mg platidiam incubated for 1 h at 37 C with 150 ml autoblood, during the next 3 d comes external irradiation per 2.6 G-r. During the 5th d of therapy one should introduce the following composition into presacral space: 60 ml 0.5%-novocaine solution, 1 ml hydrocortisone suspension, 2 ml 50%-analgin solution, 1 ml 0.01%-vitamin B12 solution, 1.6 g gentamycine, 800 mg cyclophosphan, 10 mg metothrexate. These curative impacts should be repeated at mentioned sequence four times. The method enables to decrease radiation loading and toxic manifestations of anti-tumor therapy at achieving increased percent of tumor regression.
EFFECT: higher efficiency of therapy.
1 ex